Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05678413
Other study ID # Intraurethral Paclitaxel
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2022
Est. completion date October 1, 2024

Study information

Verified date December 2022
Source Al-Azhar University
Contact Mohamed F Salman, MD
Phone +201111788996
Email prof_mohamed_fawzy@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Stricture urethra is a common disease and has various causing factors. The most common performed procedure is direct visual internal urethrotomy (DVIU), but unfortunately has a high recurrence rates. Multiple trial were performed to improve the outcomes of DVIU. Various intralesional injections were used. in this trial we will evaluate intralesional paclitaxel injection following DVIU.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date October 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Anterior urethral stricture - Short strictures (less than 2 cm) - International Prostate Symptom Score less than 11 and maximum flow rate < 15 ml per second. - No previous treatment for stricture disease Exclusion Criteria: - Recurrent cases - Prior pelvic radiation - Associated other pathology or unresolved confounding etiologies (e.g. bladder neck contracture, neurogenic bladder, benign prostatic hyperplasia) were excluded.

Study Design


Intervention

Procedure:
DVIU with paclitaxel injection
Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
DVIU
DVIU

Locations

Country Name City State
Egypt Mohamed Fawzy Salman Cairo

Sponsors (1)

Lead Sponsor Collaborator
Al-Azhar University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success of treatment Treatment free rates (Freedom from repeat intervention e.g., repeat dilation, DVIU or urethroplasty). 1 year
See also
  Status Clinical Trial Phase
Completed NCT03014726 - ROBUST I Pilot Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease Early Phase 1